SPTX · Insider Trading
Seaport Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by SPTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Denice Torres | Director | Buy | +5,000 | +$99.32K |
| 2026-06-24 | Robert J. Hombach | Director | Buy | +13,000 | +$235.77K |
| 2026-05-06 | PureTech Health plc | 10%+ Owner | C | +16,382,534 | — |
| 2026-05-04 | Sharon Mates | Director | A | +49,033 deriv. | — |
| 2026-05-04 | Steven M Paul | Director | C | +67,031 | — |
| 2026-05-04 | Daphne Zohar | Chief Executive Officer | A | +1,758,599 deriv. | — |
| 2026-05-04 | David E. Wheadon | Director | A | +12,258 deriv. | — |
| 2026-05-04 | Sandra E Peterson | Director | A | +12,258 deriv. | — |
| 2026-05-04 | Lana Gladstein | General Counsel | C | +33,515 | — |
| 2026-05-04 | Denice Torres | Director | C | +13,406 | — |
| 2026-05-04 | Lauren White | Chief Financial Officer | C | +6,702 | — |
| 2026-05-04 | Antony Loebel | Chief Medical Officer | C | +20,109 | — |
| 2026-05-04 | Michael Cunyuan Chen | Chief Scientific Officer | C | +3,351 | — |
| 2026-05-04 | James Healy | Director | C | +2,731,538 | — |
| 2026-05-04 | Robert J. Hombach | Director | A | +12,258 deriv. | — |
| 2026-05-04 | Steven Gillis | 10%+ Owner | MIXED | +6,294,951 | +$19.80M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| PureTech Health plc | 10%+ Owner | 15,719,758 | $344.66M |
| James Healy | Director | 2,731,538 | $59.89M |
| Steven Gillis | 10%+ Owner | 2,513,686 | $55.11M |
| Steven M Paul | Director | 863,031 | $18.92M |
| Lana Gladstein | General Counsel | 33,515 | $734.82K |
| Antony Loebel | Chief Medical Officer | 20,109 | $440.89K |
| Denice Torres | Director | 18,406 | $403.55K |
| Robert J. Hombach | Director | 13,000 | $285.02K |
| Lauren White | Chief Financial Officer | 6,702 | $146.94K |
| Michael Cunyuan Chen | Chief Scientific Officer | 3,351 | $73.47K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.